Trial NCT01331824

View at ClinicalTrials.gov 
Org. Study IDs: GCO 10-1341

Last trial update was posted on 2018-04-23

MeSH Interventions

Amrubicin

MeSH Conditions

Carcinoma, Transitional Cell Urinary Bladder Neoplasms

Other Conditions

Bladder Cancer

Stopping Reasons

due to a development decision by the funder

Limitations And Caveats

The trial was terminated prematurely due to the results of a phase 3 study seeking registration for amrubicin in small cell lung cancer in the United States, leading the industry funder to discontinue further clinical development of amrubicin.

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID